teensexonline.com

What’s Going On With Monopar Therapeutics (MNPR) Shares Today – Monopar Therapeutics (NASDAQ:MNPR)

Date:

  • Monopar Therapeutics Inc MNPR opened enrollment for the fifth dose level cohort in the open-label Phase 1b camsirubicin Maximum Tolerated Dose trial for advanced soft tissue sarcoma (ASTS), a diverse type of cancer that typically develops in the body’s connective tissue. 
  • The cohort dose is at an increased dose of 650 mg/m2, nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial.
  • The company said that no drug-related cardiotoxicity has been observed with camsirubicin treatment. 
  • It compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin treatment, the current first-line treatment for ASTS.
  • 17% of camsirubicin patients in the trial have experienced low-grade hair loss; another 8% have experienced over 50% hair loss, versus approximately 50% of doxorubicin-treated patients reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss.
  • 8% of camsirubicin patients in the trial have experienced low-grade mild oral mucositis compared to the roughly 35-40% of doxorubicin-treated patients.
  • “So far, camsirubicin has demonstrated a favorable safety profile at up to the 520 mg/m2 dose level assessed to date,” said Dr. Cranmer.”
  • EF Hutton writes that having established proof-of-concept in sarcoma, camsirubicin could be developed in another dozen cancer indications, where doxorubicin is still the backbone of treatment.
  • It reiterates the Buy rating and a price target of $24.
  • Price Action: MNPR shares are down 13.7% at $3.16 on the last check Tuesday.

Share post:

Subscribe

Popular

More like this
Related